ASH 2020 | Updates on FLT3-mutated AML at ASH 2020
Mark Levis
• 3 Dec 2020
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, outlines the latest updates in FLT3-mutated acute myeloid leukemia (AML) that will be presented at ASH 2020. There have been substantial research efforts focusing on mechanisms of resistance to FLT3 inhibitors, of which gilteritinib is of particular interest. Initial data from subgroup analyses in Phase III trials of gilteritinib will be presented, which have begun to identify predictors of response. Promising results of efficacious combination studies will also be discussed, such as gilteritinib with venetoclax. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
